AxonDx
Angel
AxonDx revolutionizes cancer diagnosis with nCYTE™ technology, offering fast, accurate, and cost-effective detection of Circulating Tumor Cells for personalized treatment.
Founded
2013AxonDx revolutionizes cancer diagnosis with nCYTE™ technology, offering fast, accurate, and cost-effective detection of Circulating Tumor Cells for personalized treatment.
Founded with a mission to revolutionize cancer diagnosis, AxonDx focuses on the early detection and characterization of Circulating Tumor Cells (CTCs) using their proprietary nCYTE™ technology. Their core vision is to provide fast, accurate, and cost-effective diagnostic solutions that enable personalized cancer treatment. AxonDx offers advanced research tools, including enhanced scanning optical systems powered by artificial intelligence and state-of-the-art biomarkers, to simplify the detection of rare cells in blood and other body fluids.
AxonDx has garnered attention from notable figures in the medical and biotech industries, attracting significant investment to advance their innovative diagnostic solutions. Among their key achievements is the successful implementation of nCYTE™ technology, which has shown promise in providing thorough prognostic insights into a patient's cancer. The impact of AxonDx's work is profound, offering a new avenue for early cancer detection and personalized treatment, potentially improving patient outcomes and transforming oncology diagnostics.
Companies similar to AxonDx include NanoCytomics, CDx Diagnostics, OnCirc Diagnostics and AOA Dx.
AxonDx was founded in 2013.
AxonDx's headquarters is located in Earlysville, VA, US.
AxonDx's most recent funding round was for $224.4k (USD) in May 2020.
As of May 14, 2020, AxonDx has raised a total of $224.4k (USD).
AxonDx has 6 employees as of Feb 4, 2024.
OnCirc Diagnostics
